Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has announced inducement grants to two new employees. The company's Compensation Committee approved 29,500 stock options at an exercise price of $2.80 per share and 14,750 restricted stock units (RSUs) as of July 1, 2025.
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest over three years, with one-third vesting annually. Both grants are contingent on continued employment with Protara.
Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica specializzata in terapie per il cancro e malattie rare, ha annunciato concessioni di incentivi a due nuovi dipendenti. Il Comitato per la Retribuzione dell'azienda ha approvato 29.500 opzioni azionarie con un prezzo di esercizio di 2,80 $ per azione e 14.750 unit脿 azionarie vincolate (RSU) a partire dal 1掳 luglio 2025.
Le opzioni azionarie matureranno in quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi 36 mesi. Le RSU matureranno in tre anni, con un terzo che matura ogni anno. Entrambe le concessioni sono soggette alla continuazione del rapporto di lavoro con Protara.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa cl铆nica centrada en terapias para el c谩ncer y enfermedades raras, ha anunciado concesiones de incentivos para dos nuevos empleados. El Comit茅 de Compensaci贸n de la compa帽铆a aprob贸 29,500 opciones sobre acciones con un precio de ejercicio de $2.80 por acci贸n y 14,750 unidades restringidas de acciones (RSU) a partir del 1 de julio de 2025.
Las opciones sobre acciones se consolidar谩n durante cuatro a帽os, con un 25% consolid谩ndose despu茅s del primer a帽o y el resto consolid谩ndose mensualmente durante los siguientes 36 meses. Las RSU se consolidar谩n durante tres a帽os, con un tercio consolid谩ndose anualmente. Ambas concesiones dependen de la continuidad del empleo con Protara.
Protara Therapeutics (雮橃姢雼�: TARA)電� 鞎� 氚� 頋穩 歆堩櫂 旃橂鞝滌棎 欷戩爯鞚� 霊� 鞛勳儊 雼硠 須岇偓搿�, 霊� 氇呾潣 鞁犼窚 歆侅洂鞐愱矊 鞙犾澑 氤挫儊鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 氤挫儊 鞙勳洂須岆姅 欤茧嫻 頄夓偓 臧�瓴╈澊 2.80雼煬鞚� 29,500欤� 鞀ろ啞 鞓奠厴瓿� 14,750臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 2025雲� 7鞗� 1鞚检瀽搿� 鞀轨澑頄堨姷雼堧嫟.
鞀ろ啞 鞓奠厴鞚� 4雲勳棎 瓯胳硱 甓岆Μ臧� 攵�鞐悩氅�, 1雲� 頉� 25%臧� 攵�鞐悩瓿� 雮橂ǜ歆�電� 36臧滌洈 霃欖晥 毵れ洈 攵�鞐惄雼堧嫟. RSU電� 3雲勳棎 瓯胳硱 甓岆Μ臧� 攵�鞐悩氅�, 毵る厔 3攵勳潣 1鞌� 攵�鞐惄雼堧嫟. 霊� 氤挫儊 氇憪 Protara鞐愳劀 瓿勳啀 攴茧頃橂姅 臁瓣贝鞐� 霐半澕 歆�旮夒惄雼堧嫟.
Protara Therapeutics (Nasdaq : TARA), une soci茅t茅 en phase clinique sp茅cialis茅e dans les th茅rapies contre le cancer et les maladies rares, a annonc茅 des attributions incitatives 脿 deux nouveaux employ茅s. Le comit茅 de r茅mun茅ration de l'entreprise a approuv茅 29 500 options d'achat d'actions 脿 un prix d'exercice de 2,80 $ par action et 14 750 unit茅s d'actions restreintes (RSU) 脿 compter du 1er juillet 2025.
Les options d'achat d'actions seront acquises sur une p茅riode de quatre ans, avec 25 % acquis apr猫s un an et le reste acquis mensuellement sur 36 mois. Les RSU seront acquises sur trois ans, avec un tiers acquis chaque ann茅e. Les deux attributions sont conditionn茅es 脿 la poursuite de l'emploi chez Protara.
Protara Therapeutics (Nasdaq: TARA), ein klinisch fortgeschrittenes Unternehmen, das sich auf Krebs- und seltene Krankheitsbehandlungen spezialisiert hat, hat Anreizzuteilungen f眉r zwei neue Mitarbeiter bekannt gegeben. Der Verg眉tungsausschuss des Unternehmens genehmigte 29.500 Aktienoptionen zu einem Aus眉bungspreis von 2,80 $ pro Aktie sowie 14.750 Restricted Stock Units (RSUs) mit Wirkung zum 1. Juli 2025.
Die Aktienoptionen werden 眉ber vier Jahre vesten, wobei 25 % nach einem Jahr vesten und der Rest monatlich 眉ber 36 Monate verteilt. Die RSUs vesten 眉ber drei Jahre, wobei jeweils ein Drittel j盲hrlich vestet. Beide Zuteilungen setzen eine fortlaufende Anstellung bei Protara voraus.
- None.
- None.
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (鈥淧rotara鈥� or the 鈥淐ompany鈥�), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees.
The Compensation Committee of Protara鈥檚 Board of Directors approved an aggregate of 29,500 stock option awards and 14,750 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees鈥� employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on July 1, 2025 and have an exercise price of
All option awards vest over four years, with
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara鈥檚 portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or na茂ve to treatment with Bacillus Calmette-Gu茅rin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit
Company Contact:
Justine O'Malley
Protara Therapeutics
646-817-2836
Source: Protara Therapeutics
FAQ
What type of inducement grants did Protara Therapeutics (TARA) announce on July 1, 2025?
What is the vesting schedule for Protara Therapeutics' (TARA) new stock option grants?
How do the RSUs vest in Protara Therapeutics' (TARA) July 2025 inducement grants?
What was the exercise price for Protara Therapeutics' (TARA) July 2025 stock option grants?
